NeuroStemcell (European Consortium for Stem Cell Therapy in Neurodegenerative Diseases)
is a 4-year FP7 European Union funded Project which has been awarded a total budget of 11.9 million €, led by Coordinator Prof. Elena Cattaneo – University of Milan and Deputy Coordinator Prof. Anders Björklund – Lund University.
NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application, with the goal to develop safe and validated cells and clinical grade reagents to be used in clinical trials and eventually in drug discovery.
NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
NeuroStemcell encourages participation at meetings, summer schools, short-term exchange visits and interactions among laboratories through an attractive Outreach and Training programme. This will facilitate early-career exposure to different techniques, methods and scientific approaches. The Consortium also includes an ethics programme and the development of a road.